From the bench to bedside: biological and methodology considerations for the future of companion diagnostics in nonsmall cell lung cancer.
From the bench to bedside: biological and methodology considerations for the future of companion diagnostics in nonsmall cell lung cancer.
复制标题
DOI：
10.4061/2011/312346
复制
发表时间：
2011
期刊：
影响因子：
--
通讯作者：
Syrigos KN
中科院分区：
文献类型：
--
作者：
Dimou A;Harrington K;Syrigos KN
伴随诊断是肿瘤患者护理中一个新兴且令人兴奋的领域。这些测试伴随着癌症患者的标准诊断调查，并作为治疗决策的辅助手段。大量的新化合物正在非小细胞肺癌（NSCLC）的临床和实验室测试中。随着治疗选择的多样性在疾病的各种环境中扩展，很明显，特异性和敏感性的分子测试是必要的，以确定将获得临床益处的患者子集。检测表皮生长因子受体（EGFR）体细胞突变以适当给予酪氨酸激酶抑制剂只是一个开始。间变性淋巴瘤激酶（ALK）融合蛋白检测和分子组织学分类分别是克唑替尼和培美曲塞临床获益的有前景的候选预测指标。本文总结了这样的诊断，并讨论了未回答的问题，有关基础生物学和标准化问题。
Companion diagnostics are an emerging and exciting field in the care of oncology patients. These tests accompany standard diagnostic investigations in cancer patients and function as an aid in treatment decision making. A great number of new compounds are under clinical and laboratory testing in nonsmall cell lung cancer (NSCLC). As the variety of therapeutic options expands in the various settings of the disease, it becomes apparent that specific and sensitive molecular tests are necessary to define the subsets of patients who are going to derive clinical benefit. Testing for epidermal growth factor receptor (EGFR) somatic mutations for the appropriate administration of tyrosine kinase inhibitors is just the beginning. Anaplastic lymphoma kinase (ALK) fusion protein detection and molecular histology classification are promising candidate predictors for clinical benefit from crizotinib and pemetrexed, respectively. This paper summarizes such diagnostics and discusses unanswered questions concerning underlying biology and standardization issues.